Carboxypeptidase B2
From Wikipedia, the free encyclopedia
Carboxypeptidase B2 (plasma)
|
||||||||||||||
Identifiers | ||||||||||||||
Symbol(s) | CPB2; PCPB; CPU; TAFI | |||||||||||||
External IDs | OMIM: 603101 MGI: 1891837 HomoloGene: 55610 | |||||||||||||
|
||||||||||||||
RNA expression pattern | ||||||||||||||
Orthologs | ||||||||||||||
Human | Mouse | |||||||||||||
Entrez | 1361 | 56373 | ||||||||||||
Ensembl | ENSG00000080618 | ENSMUSG00000021999 | ||||||||||||
Uniprot | Q96IY4 | Q9JHH6 | ||||||||||||
Refseq | NM_001872 (mRNA) NP_001863 (protein) |
NM_019775 (mRNA) NP_062749 (protein) |
||||||||||||
Location | Chr 13: 45.53 - 45.58 Mb | Chr 14: 73.98 - 74.02 Mb | ||||||||||||
Pubmed search | [1] | [2] |
Carboxypeptidase B2 (plasma), also known as CPB2, is a human gene.
Carboxypeptidases are enzymes that hydrolyze C-terminal peptide bonds. The carboxypeptidase family includes metallo-, serine, and cysteine carboxypeptidases. According to their substrate specificity, these enzymes are referred to as carboxypeptidase A (cleaving aliphatic residues) or carboxypeptidase B (cleaving basic amino residues). The protein encoded by this gene is activated by trypsin and acts on carboxypeptidase B substrates. After thrombin activation, the mature protein downregulates fibrinolysis. Polymorphisms have been described for this gene and its promoter region. Available sequence data analyses indicate splice variants that encode different isoforms.[1]
[edit] See also
[edit] References
[edit] Further reading
- Bouma BN, Mosnier LO (2005). "Thrombin activatable fibrinolysis inhibitor (TAFI) at the interface between coagulation and fibrinolysis.". Pathophysiol. Haemost. Thromb. 33 (5-6): 375-81. doi: . PMID 15692247.
- Marinkovic DV, Marinkovic JN, Erdös EG, Robinson CJ (1977). "Purification of carboxypeptidase B from human pancreas.". Biochem. J. 163 (2): 253-60. PMID 17398.
- Tsai SP, Drayna D (1992). "The gene encoding human plasma carboxypeptidase B (CPB2) resides on chromosome 13.". Genomics 14 (2): 549-50. PMID 1427879.
- Eaton DL, Malloy BE, Tsai SP, et al. (1991). "Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma.". J. Biol. Chem. 266 (32): 21833-8. PMID 1939207.
- Pascual R, Burgos FJ, Salva M, et al. (1989). "Purification and properties of five different forms of human procarboxypeptidases.". Eur. J. Biochem. 179 (3): 609-16. PMID 2920728.
- Valnickova Z, Thogersen IB, Christensen S, et al. (1996). "Activated human plasma carboxypeptidase B is retained in the blood by binding to alpha2-macroglobulin and pregnancy zone protein.". J. Biol. Chem. 271 (22): 12937-43. PMID 8662763.
- Bajzar L, Morser J, Nesheim M (1996). "TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex.". J. Biol. Chem. 271 (28): 16603-8. PMID 8663147.
- Vanhoof G, Wauters J, Schatteman K, et al. (1997). "The gene for human carboxypeptidase U (CPU)--a proposed novel regulator of plasminogen activation--maps to 13q14.11.". Genomics 38 (3): 454-5. doi: . PMID 8975730.
- Zhao L, Morser J, Bajzar L, et al. (1999). "Identification and characterization of two thrombin-activatable fibrinolysis inhibitor isoforms.". Thromb. Haemost. 80 (6): 949-55. PMID 9869166.
- Boffa MB, Reid TS, Joo E, et al. (1999). "Characterization of the gene encoding human TAFI (thrombin-activable fibrinolysis inhibitor; plasma procarboxypeptidase B).". Biochemistry 38 (20): 6547-58. doi: . PMID 10350473.
- Matsumoto A, Itoh K, Matsumoto R (2000). "A novel carboxypeptidase B that processes native beta-amyloid precursor protein is present in human hippocampus.". Eur. J. Neurosci. 12 (1): 227-38. PMID 10651877.
- Marx PF, Hackeng TM, Dawson PE, et al. (2000). "Inactivation of active thrombin-activable fibrinolysis inhibitor takes place by a process that involves conformational instability rather than proteolytic cleavage.". J. Biol. Chem. 275 (17): 12410-5. PMID 10777524.
- Mosnier LO, Lisman T, van den Berg HM, et al. (2002). "The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration.". Thromb. Haemost. 86 (4): 1035-9. PMID 11686321.
- Mosnier LO, Meijers JC, Bouma BN (2002). "The role of protein S in the activation of thrombin activatable fibrinolysis inhibitor (TAFI) and regulation of fibrinolysis.". Thromb. Haemost. 86 (4): 1040-6. PMID 11686322.
- Mosnier LO, Elisen MG, Bouma BN, Meijers JC (2002). "Protein C inhibitor regulates the thrombin-thrombomodulin complex in the up- and down regulation of TAFI activation.". Thromb. Haemost. 86 (4): 1057-64. PMID 11686324.
- Morange PE, Aillaud MF, Nicaud V, et al. (2002). "Ala147Thr and C+1542G polymorphisms in the TAFI gene are not associated with a higher risk of venous thrombosis in FV Leiden carriers.". Thromb. Haemost. 86 (6): 1583-4. PMID 11776333.
- Schneider M, Nagashima M, Knappe S, et al. (2002). "Amino acid residues in the P6-P'3 region of thrombin-activable fibrinolysis inhibitor (TAFI) do not determine the thrombomodulin dependence of TAFI activation.". J. Biol. Chem. 277 (12): 9944-51. doi: . PMID 11786552.
- Koschinsky ML, Boffa MB, Nesheim ME, et al. (2002). "Association of a single nucleotide polymorphism in CPB2 encoding the thrombin-activable fibrinolysis inhibitor (TAF1) with blood pressure.". Clin. Genet. 60 (5): 345-9. PMID 11903334.
- Yano Y, Gabazza EC, Hori Y, et al. (2002). "Association between plasma thrombin-activatable fibrinolysis inhibitor levels and activated protein C in normotensive type 2 diabetic patients.". Diabetes Care 25 (7): 1245-6. PMID 12087030.
- Antovic JP, Blombäck M (2003). "Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation.". Thromb. Res. 106 (1): 59-62. PMID 12165290.
This article incorporates text from the United States National Library of Medicine, which is in the public domain.
|